Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermira Inc.

www.dermira.com

Latest From Dermira Inc.

No Sweat – Hyperhidrosis Patients Seek Broader Approvals; Botox Access An Issue

US FDA not looking to reduce attendance at third-party patient meetings, which deliver 'bang for the buck.' Excessive sweating is first externally led PFDD meeting for a more common condition.

Drug Approval Standards Dermatology

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals

Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.

Deals M & A

Dermira Ends UCB Cimzia Psoriasis Pact To Focus On Its Own Pipeline

As it ends its pact with UCB, Dermira says it needs to focus on its own top assets and couldn't simultaneously launch Cimzia in psoriasis.

Business Strategies Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Skintelligence Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dermira Inc.
  • Senior Management
  • Thomas G Wiggans, CEO
    Andrew Guggenhime , COO & CFO
    Eugene A Bauer, MD, CMO
    Chris Griffith, VP, Corp. Dev. & Strategy
    Christine Conroy , SVP, Reg. Affairs
    Hans Hofland, PhD, VP, Research & Nonclinical Dev.
    Lori Lyons-Williams, Chief Commercial Officer
  • Contact Info
  • Dermira Inc.
    Phone: (650) 421-7200
    275 Middlefield Rd.
    Ste. 150
    Menlo Park, CA 94025
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register